Peptide for inhibiting dipeptidyl-peptidase iv
AssigneeChina Medical University
InventorsKuo-Chiang HSU, Kit-Pan HO, Shih-Li HUANG, Chia-Ling JAO
Life of this patent
Estimating the term…
Abstract
A method for inhibiting dipeptidyl-peptidase IV is provided and includes administering a peptide to the dipeptidyl-peptidase IV, in which the peptide is isolated from a gelatin hydrolysate produced by enzymatic digestion with alcalase (ALA), bromelain (BRO), and flavourzyme (FLA).
Claims19
A method for inhibiting dipeptidyl-peptidase IV comprising:
- administering an effective amount of a peptide to the dipeptidyl-peptidase IV, wherein the peptide is isolated from a gelatin hydrolysate produced by enzymatic digestion with bromelain (BRO), or flavourzyme (FLA) and comprises four amino acid residues with an amino acid sequence of
- Gly-Pro-X3-X4 (SEQ ID NO:
- 1), wherein
- X3 is alanine or glycine;
- and
- X4 is glutamate or alanine.
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating type 2 diabetes, comprising administering an effective amount of a peptide to an animal, wherein the peptide isolated from a gelatin hydrolysate produced by enzymatic digestion with bromelain (BRO), or flavourzyme (FLA) and comprises four amino acid residues and has an amino acid sequence of
- Gly-Pro-X3-X4 (SEQ ID NO:
- 1), wherein
- X3 is alanine or glycine;
- and
- X4 glutamate or alanine.
A pharmaceutical composition comprising a peptide isolated from a gelatin hydrolysate produced by enzymatic digestion with bromelain (BRO), or flavourzyme (FLA) includes four amino acid residues having an amino acid sequence of
- Gly-Pro-X3-X4 (SEQ ID NO:
- wherein
- X3 is alanine or glycine;
- and
- X4 is glutamate or alanine.
Dependencies are inferred from the claim text.